ImmuCell Co. (NASDAQ:ICCC) Short Interest Update

ImmuCell Co. (NASDAQ:ICCC) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 8,500 shares, a decrease of 54.3% from the August 31st total of 18,600 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 35,800 shares, the short-interest ratio is currently 0.2 days.

ImmuCell Price Performance

Shares of ImmuCell stock traded down $0.06 during trading on Friday, hitting $3.55. The stock had a trading volume of 16,710 shares, compared to its average volume of 18,958. The firm has a market cap of $27.73 million, a price-to-earnings ratio of -6.96 and a beta of 0.56. ImmuCell has a 12 month low of $3.34 and a 12 month high of $5.59. The business’s 50-day moving average is $3.79 and its 200 day moving average is $4.43. The company has a current ratio of 2.37, a quick ratio of 0.77 and a debt-to-equity ratio of 0.42.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.20) earnings per share for the quarter. The business had revenue of $5.47 million during the quarter. ImmuCell had a negative net margin of 17.44% and a negative return on equity of 16.35%.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Mesirow Financial Investment Management Inc. bought a new position in ImmuCell Co. (NASDAQ:ICCC) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.